Abstract
This paper focuses on the processes and strategies of advocates and opponents in creating, maintaining and/or contesting the protective spaces in which 'urgently needed' but 'risky' pharmaceutical innovations are managed. Drawing on transition literature and recent work on niche protection, this paper adds to the conceptualisation and empirical grounding of
... read more